Michael Aberman
Gründer bei Xenimmune Therapeutics, Inc.
Profil
Dr. Michael S.
Aberman is a General Partner at Regeneron Ventures and a Chief Executive Officer & Director at Xenimmune Therapeutics, Inc. He is on the Board of Directors at Halomine, Inc. and Xenimmune Therapeutics, Inc.
Dr. Aberman was previously employed as a Senior VP-Strategy & Investor Relations by Regeneron Pharmaceuticals, Inc., a Research Analyst by Credit Suisse Securities (USA) LLC (Broker), a Research Associate by Morgan Stanley & Co., Inc., a Director-Business Development by Antigenics, Inc. (Delaware), and a President & Chief Executive Officer by Quentis Therapeutics, Inc.
He received his undergraduate degree from Cornell University, an MBA from The Wharton School of the University of Pennsylvania and a doctorate degree from the University of Toronto.
Aktive Positionen von Michael Aberman
Unternehmen | Position | Beginn |
---|---|---|
Halomine, Inc.
Halomine, Inc. Industrial SpecialtiesProcess Industries Halomine, Inc. manufactures chlorine disinfectants for surfaces and medical devices. It offers halofilm, halocare, and halocoat. The company was founded in 2018 and is headquartered in Ithaca, NY. | Direktor/Vorstandsmitglied | 03.11.2021 |
Xenimmune Therapeutics, Inc.
Xenimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xenimmune Therapeutics, Inc. develops antibody-enzyme fusion to target tumors and trigger the hyper-acute rejection. The private company is located in the US. | Gründer | - |
Ehemalige bekannte Positionen von Michael Aberman
Unternehmen | Position | Ende |
---|---|---|
Credit Suisse Securities (USA) LLC (Broker)
Credit Suisse Securities (USA) LLC (Broker) Investment Banks/BrokersFinance Credit Suisse Securities (USA) LLC (Credit Suisse Securities USA) is the broker/dealer division of Credit Suisse Securities (USA) LLC, an investment banking company headquartered in New York City. The firm was founded in 1998 and is a wholly owned subsidiary of Credit Suisse (USA), Inc., ultimately owned by Credit Suisse Group AG (SWX: CSGN) in Switzerland. Credit Suisse Securities USA offers a suite of equities, solutions and credit products and services which includes global securities sales, trading and execution, prime brokerage and comprehensive investment research. Their clients include financial institutions, corporations, governments, institutional investors, such as pension funds and hedge funds, and private individuals around the world. | Analyst-Equity | 21.03.2010 |
Morgan Stanley & Co. LLC
Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry. | Analyst-Equity | 31.05.2006 |
AGENUS INC. | Corporate Officer/Principal | 01.03.2004 |
Quentis Therapeutics, Inc.
Quentis Therapeutics, Inc. BiotechnologyHealth Technology Quentis Therapeutics, Inc. operates as a biotechnology company. It develops therapeutics in the onco-immunology field. The company was founded by Juan R. cubillos-Ruiz and is headquartered in New York, NY. | Vorstandsvorsitzender | - |
REGENERON PHARMACEUTICALS, INC. | Investor Relations Kontakt | - |
Ausbildung von Michael Aberman
Cornell University | Undergraduate Degree |
University of Toronto | Doctorate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
REGENERON PHARMACEUTICALS, INC. | Health Technology |
AGENUS INC. | Health Technology |
Private Unternehmen | 5 |
---|---|
Credit Suisse Securities (USA) LLC (Broker)
Credit Suisse Securities (USA) LLC (Broker) Investment Banks/BrokersFinance Credit Suisse Securities (USA) LLC (Credit Suisse Securities USA) is the broker/dealer division of Credit Suisse Securities (USA) LLC, an investment banking company headquartered in New York City. The firm was founded in 1998 and is a wholly owned subsidiary of Credit Suisse (USA), Inc., ultimately owned by Credit Suisse Group AG (SWX: CSGN) in Switzerland. Credit Suisse Securities USA offers a suite of equities, solutions and credit products and services which includes global securities sales, trading and execution, prime brokerage and comprehensive investment research. Their clients include financial institutions, corporations, governments, institutional investors, such as pension funds and hedge funds, and private individuals around the world. | Finance |
Morgan Stanley & Co. LLC
Morgan Stanley & Co. LLC Investment Banks/BrokersFinance Morgan Stanley & Co. LLC is a registered broker-dealer subsidiary of Morgan Stanley Domestic Holdings, Inc., ultimately owned by Morgan Stanley (NYSE: MS) in the US. Headquartered in New York City, the firm was founded in 1987 and provides debt and equity services including underwriting, M&A advice, securities dealing and brokerage and trade execution. Their client base ranges from large global institutional investors to hedge funds at the cutting edge of innovation in the industry. | Finance |
Quentis Therapeutics, Inc.
Quentis Therapeutics, Inc. BiotechnologyHealth Technology Quentis Therapeutics, Inc. operates as a biotechnology company. It develops therapeutics in the onco-immunology field. The company was founded by Juan R. cubillos-Ruiz and is headquartered in New York, NY. | Health Technology |
Halomine, Inc.
Halomine, Inc. Industrial SpecialtiesProcess Industries Halomine, Inc. manufactures chlorine disinfectants for surfaces and medical devices. It offers halofilm, halocare, and halocoat. The company was founded in 2018 and is headquartered in Ithaca, NY. | Process Industries |
Xenimmune Therapeutics, Inc.
Xenimmune Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Xenimmune Therapeutics, Inc. develops antibody-enzyme fusion to target tumors and trigger the hyper-acute rejection. The private company is located in the US. | Health Technology |